ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Translational Lung Cancer Research

• Publication date

  2014-05-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.3978/j.issn.2218-6751.2014.03.01PMID 25806308PMCID PMC4367701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.

  2014cited by this paper
• An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators

  2014influential reference
• Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

  2013influential reference
• Clinical response to crizotinib retreatment after acquisition of drug resistance.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013influential reference
• A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

  2013cited by this paper
• Immunohistochemical Profiling of ALK Fusion Gene–Positive Adenocarcinomas of the Lung

  2013influential reference
• Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization

  2013influential reference
• Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients

  2013influential reference
• CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

  2013cited by this paper
• Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan

  2013cited by this paper
• Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.

  2012cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012influential reference
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

  2012influential reference
• Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

  2012cited by this paper
• Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

  2012cited by this paper
• Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma

  2012cited by this paper
• Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optima

  2012cited by this paper
• RET, ROS1 and ALK fusions in lung cancer

  2012cited by this paper
• Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

  2012cited by this paper
• A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.

  2012cited by this paper
• Clinical Activity of Crizotinib in Patients with Advanced Non-small Cell Lung Cancer Harboring ROS1 Gene Rearrangement

  2012cited by this paper
• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

  2012cited by this paper
• Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC).

  2012cited by this paper
• Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)

  2012cited by this paper
• Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC

  2012cited by this paper
• Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.

  2012cited by this paper
• ROS1 rearrangements define a unique molecular class of lung cancers.

  2012cited by this paper
• ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

  2012cited by this paper
• Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion

  2012cited by this paper
• Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors

  2012cited by this paper
• A First-In-Human Dose-Finding Study of the Alk/Egfr Inhibitor AP26113 in Patients with Advanced Malignancies

  2012cited by this paper
• A Phase I/II Study of Alk Inhibitor CH5424802 in Patients With Alk-Positive Nsclc; Safety and Efficacy Interim Results of the Phase II Portion

  2012cited by this paper
• Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)

  2012cited by this paper
• Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

  2012cited by this paper
• Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).

  2012cited by this paper
• Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

  2012cited by this paper
• Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

  2011cited by this paper
• A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

  2011cited by this paper
• Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

  2011cited by this paper
• Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

  2011cited by this paper
• CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

  2011cited by this paper
• Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

  2011cited by this paper
• Clinical Implications of High MET Gene Dosage in Non-Small Cell Lung Cancer Patients without Previous Tyrosine Kinase Inhibitor Treatment

  2011cited by this paper
• CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

  2011cited by this paper
• ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.

  2011cited by this paper
• Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors

  2011cited by this paper
• The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

  2011cited by this paper
• Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

  2011cited by this paper
• Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH

  2011influential reference
• Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

  2011cited by this paper
• Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

  2010cited by this paper
• The biology and treatment of EML4-ALK non-small cell lung cancer.

  2010cited by this paper
• Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066)

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth*

  2010cited by this paper
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

  2010influential reference
• Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

  2010cited by this paper
• MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

  2009influential reference
• Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066.

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009influential reference
• KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

  2009cited by this paper
• Activation of tyrosine kinases by mutation of the gatekeeper threonine

  2008cited by this paper
• The anaplastic lymphoma kinase in the pathogenesis of cancer

  2008cited by this paper
• Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007influential reference
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Identification and Characterization of a Nuclear Interacting Partner of Anaplastic Lymphoma Kinase (NIPA)*

  2003cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper

• Advances of dual inhibitors based on ALK for the treatment of cancer.

  2025cites this paper
• An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors

  2025cites this paper
• Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs

  2023cites this paper
• Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario

  2023cites this paper
• Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings

  2022cites this paper
• The lncRNA OGFRP1/miR-149-5p/IL-6 axis regulates prostate cancer chemoresistance.

  2021cites this paper
• OTT_A_291801 3037..3049

  2021cites this paper
• A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

  2021cites this paper
• Efficacy and safety of ceritinib in anaplastic lymphoma kinase‐rearranged non‐small cell lung cancer: A systematic review and meta‐analysis

  2020cites this paper
• Molecular tumor board: Case 2 – Evolution of resistance in anaplastic lymphoma kinase driven non-small-cell lung carcinoma

  2020cites this paper
• cacy of combination treatment using YHO-1701 , an orally active STAT 3 inhibitor , with molecular-targeted agents on cancer cell lines

  2020cites this paper
• Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines

  2020cites this paper
• Targeting the splice factor kinase CLK1 in prostate cancer cells

  2020cites this paper
• EML4–ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7

  2020cites this paper
• New generation anaplastic lymphoma kinase inhibitors.

  2019cites this paper
• Gene Fusion in NSCLC

  2019cites this paper
• EML4-ALK V3 drives cell migration through NEK9 and NEK7 kinases in non-small-cell lung cancer

  2019cites this paper
• Epithelial‐to‐mesenchymal transition in the context of epidermal growth factor receptor inhibition in non‐small‐cell lung cancer

  2018cites this paper
• Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.

  2018cites this paper
• Importance of anaplastic lymphoma kinase gene re-arrangements on non-small cell lung cancer

  2017cites this paper
• Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it

  2017cites this paper
• Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling

  2017cites this paper
• Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR

  2017cites this paper
• Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

  2017cites this paper
• Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review).

  2017influential citation
• Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

  2017cites this paper
• ALK gene alterations in cancer: biological aspects and therapeutic implications.

  2017cites this paper
• Development of a new choroidal metastasis in resistance to crizotinib therapy in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

  2017cites this paper
• Long non-coding RNA NEAT1 contributes to docetaxel resistance of prostate cancer through inducing RET expression by sponging miR-34a

  2017cites this paper
• Targeting asparagine and autophagy for pulmonary adenocarcinoma therapy

  2016cites this paper
• Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies.

  2016cites this paper
• A new look at the ALK gene in cancer: copy number gain and amplification

  2016cites this paper
• Assessment of ALK gene fusions in lung cancer using the differential expression and exon integrity methods.

  2016cites this paper
• Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

  2016cites this paper
• Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine

  2016cites this paper
• The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

  2016cites this paper
• Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.

  2016cites this paper
• Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).

  2016cites this paper
• Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs

  2016cites this paper
• On the pharmacogenetics of non-small cell lung cancer treatment

  2016cites this paper
• Effective Combined Treatment with Aqueous Extract of Taxuschinensis var.mairei (AETC) and Gefitinib in Inhibiting Non-SmallCell Lung Cancer PC9, PC9/R Cell Lines In Vitro and In Vivo

  2016cites this paper
• Nintedanib in NSCLC: evidence to date and place in therapy

  2016cites this paper
• Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC

  2016influential citation
• ALK e Cancro do Pulmão: o futuro é hoje?

  2016cites this paper
• Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?

  2016cites this paper
• The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

  2016cites this paper
• Clinical potential of gene mutations in lung cancer

  2015cites this paper
• Lung Cancer Biomarkers.

  2015cites this paper
• Durability of Kinase-Directed Therapies—A Network Perspective on Response and Resistance

  2015cites this paper
• An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.

  2015cites this paper
• Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.

  2015cites this paper
• Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling.

  2015cites this paper
• Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?

  2015cites this paper
• Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?

  2014cites this paper
• Highlights from the literature

  2013cites this paper